Reeds SEC Filings

Reed’s, Inc. announced an underwritten public offering and an exchange uplisting. The company sold 2,500,000 shares of common stock together with warrants to purchase 2,500,000 shares, with each share-and-warrant unit priced at $4.00. Underwriters also partially exercised an overallotment option for additional warrants to purchase 375,000 shares. All securities were sold by Reed’s, generating approximately $9.0 million in net proceeds.

The company plans to use these funds, along with existing cash, to support growth initiatives, working capital, general corporate purposes and possible debt repayment. The warrants are immediately exercisable at $4.50 per share and expire on December 8, 2030, subject to 4.99% or 9.99% ownership limits. Reed’s controlling stockholder, D&D Source of Life Holding Ltd., and its affiliates bought about $5.0 million of the offering. In connection with the deal, Reed’s common stock was approved for listing on the NYSE American and began trading there, ending its quotation on the OTCQX market, and the company’s Second Amended and Restated Bylaws became effective.

Reed’s, Inc. filed Amendment No. 2 to its Form S-1 registration statement. This update is purely administrative and is intended to support the pending offering already described in the previously filed preliminary prospectus.

The company states that the sole purpose of this amendment is to add two exhibits: a Form of Warrant Agency Agreement as Exhibit 4.6 and the Filing Fee Table as Exhibit 107. Reed’s confirms there are no changes to the preliminary prospectus in Part I or to Items 13, 14, 15 or 17 in Part II, meaning the business terms and risk disclosures for the planned offering remain the same.

Reed’s, Inc. is conducting an underwritten public offering of 1,582,280 shares of common stock together with warrants to purchase up to 1,582,280 additional shares. All units are being sold by the company, which expects net proceeds of about $9.0 million, or approximately $10.4 million if the underwriters fully exercise a 45‑day option to buy up to 237,342 extra shares and warrants, assuming a $6.32 offering price per share and warrant.

The company plans to use the cash, along with existing liquidity, to fund growth initiatives, working capital and general corporate purposes, which may include debt repayment. After the deal, Reed’s expects about 10,527,734 shares outstanding, or 10,765,076 shares if the option is fully exercised, not including any warrant exercises. The offering is conditioned on approval to list the stock on the NYSE American under the symbol “REED”; the shares currently trade on the OTCQX Best Market. In October 2025 Reed’s completed a 1‑for‑6 reverse stock split to support its listing and capital strategy.

Reed's, Inc. filed a Form 3 initial statement of beneficial ownership. The filing reports that an officer identified as Chf. Go-To-Market & Cust. Ofcr held no securities as of the event date 11/03/2025. The form was filed by one reporting person and includes Exhibit 24 – Power of Attorney. The issuer is Reed's, Inc. (REED).

Reed’s, Inc. filed an S-1 for a primary offering of 1,326,260 shares of common stock. The deal is on a firm commitment basis and is conditioned on NYSE American listing approval. The company currently trades on OTCQX under “REED.”

The underwriters have a 45‑day option to buy up to 198,939 additional shares. Based on an assumed price of $7.54, Reed’s estimates net proceeds of about $9.0 million (or about $10.4 million if the option is exercised in full). The company plans to use proceeds for growth initiatives, working capital and other general corporate purposes, which may include debt repayment.

Reed’s effected a 1‑for‑6 reverse stock split on October 31, 2025. Shares outstanding were 8,945,454 as of September 30, 2025. Total common stock to be outstanding immediately after the offering is expected to be 10,271,714, or 10,470,653 if the option is exercised in full.

Reed’s, Inc. reported third-quarter results and updated its capital structure. Q3 net sales were $7.033 million, up 4% year over year, with gross margin at 17%. Operating loss was $4.103 million and net loss was $3.982 million (loss per share $0.48).

For the nine months ended September 30, 2025, net sales were $26.585 million (down 6%), cost of goods sold rose 7%, and gross margin was 20%. Net loss was $12.061 million and cash used in operations totaled $13.230 million, driven in part by $1.775 million of inventory write‑offs tied to product portfolio changes.

Liquidity actions included two private placements—$3.0 million in June (537,632 shares) and $5.0 million in September (833,330 shares). Cash was $4.136 million at September 30, 2025. The Senior Secured Loan was amended: the revolving commitment was reduced to $9.250 million, interest is now paid monthly, and maturity was extended to September 30, 2026; outstanding principal was $9.250 million with $0 remaining availability. On October 31, 2025, the company effected a 1‑for‑6 reverse stock split, and had 8,945,454 common shares outstanding as of October 31, 2025.

Reed’s, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and covers the company’s recent operating performance.

The information was furnished, not filed, under Item 2.02 and therefore is not subject to Section 18 liability nor automatically incorporated by reference into other filings unless specifically referenced.

Reed’s, Inc. implemented a 1-for-6 reverse stock split of its common stock, effective October 31, 2025 at 5:00 p.m. Eastern Time. The split does not change the number of authorized shares.

After effectiveness, there were approximately 8,945,620 shares outstanding prior to eliminating fractional shares. The stock will begin trading on a split-adjusted basis on the OTCQX Best Market on November 3, 2025. The new CUSIP is 758338404. A stockholder holding approximately 52.8% previously authorized the Board’s discretion to set a ratio between 1-for-3 and 1-for-9.